In clinical trials, the administration of ipilimumab and BMS-936,559 (an anti-PD-L1 monoclonal antibody) showed poor anti-tumor effects in advanced pancreatic cancer cases [32–34]. Here, CD274 is linked to pancreatic neoplasm.